BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 22211772)

  • 21. Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
    Auclair AL; Kleven MS; Barret-Grévoz C; Barreto M; Newman-Tancredi A; Depoortère R
    Behav Brain Res; 2009 Nov; 203(2):288-95. PubMed ID: 19464324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment.
    Ekinci O; Sabuncuoglu O
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):648-9. PubMed ID: 21134409
    [No Abstract]   [Full Text] [Related]  

  • 23. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
    Adan-Manes J; Garcia-Parajua P
    J Clin Pharm Ther; 2009 Apr; 34(2):245-6. PubMed ID: 19250146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agitation associated with aripiprazole initiation.
    Lea JW; Stoner SC; Lafollette J
    Pharmacotherapy; 2007 Sep; 27(9):1339-42. PubMed ID: 17723088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
    Hoffer ZS; Roth RL; Mathews M
    Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Worsening schizoaffective disorder with aripiprazole.
    Reeves RR; Mack JE
    Am J Psychiatry; 2004 Jul; 161(7):1308. PubMed ID: 15229073
    [No Abstract]   [Full Text] [Related]  

  • 31. Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.
    Chung YC; Park TW; Yang JC; Huang GB; Zhao T; Oh KY; Kim MG
    J Clin Psychopharmacol; 2012 Dec; 32(6):778-86. PubMed ID: 23131890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in tardive dyskinesia with aripiprazole use.
    Witschy JK; Winter AS
    Can J Psychiatry; 2005 Mar; 50(3):188. PubMed ID: 15830835
    [No Abstract]   [Full Text] [Related]  

  • 33. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole, a novel atypical antipsychotic drug.
    Argo TR; Carnahan RM; Perry PJ
    Pharmacotherapy; 2004 Feb; 24(2):212-28. PubMed ID: 14998222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
    Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
    J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison.
    Cianchetti C; Ledda MG
    Psychiatry Res; 2011 Oct; 189(3):349-56. PubMed ID: 21570128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
    den Boon FS; Body S; Hampson CL; Bradshaw CM; Szabadi E; de Bruin N
    J Psychopharmacol; 2012 Sep; 26(9):1231-43. PubMed ID: 21969105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of aripiprazole and tardive dyskinesia.
    Abbasian C; Power P
    J Psychopharmacol; 2009 Mar; 23(2):214-5. PubMed ID: 18515468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
    Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
    Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.